Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Executive Summary
Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.
You may also be interested in...
Back To School: Big Pharmas Test New Models For Tapping Academia
Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.
Back To School: Big Pharmas Test New Models For Tapping Academia
Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.
Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
Pfizer doesn't exactly do things by halves. Two years after pulling off the sector's biggest merger, it now appears to be carrying out the largest-scale – and most ambitious – academic tie-up yet.